drugset / Trial / NCT00275951
Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer
Phase 2
Completed
39 enrolled
National Taiwan University Hospital
Chang Gung Memorial Hospital · collabNational Health Research Institutes, Taiwan · collabTaipei Veterans General Hospital, Taiwan · collabTri-Service General Hospital (TSGH) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The investigators have initial evidence that the combination of cetuximab and cisplatin-HDFL may further improve the efficacy of the cisplatin-HDFL combination chemotherapy.
Timeline
- Start
- 2005-12
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 35 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 300 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2000 mg/m2 | Intravenous |